Navigation Links
For ST-Elevation Myocardial Infarction (STEMI), Interviewed Experts Indicate That The Medicines Company's Angiomax/Angiox Has Efficacy Advantages Over Sales-Leading ReoPro
Date:4/23/2009

Angiomax/Angiox Will Retain Decision Resources' Gold-Standard Status in 2017 for the Treatment of STEMI with Percutaneous Coronary Intervention, According to a New Report from Decision Resources

WALTHAM, Mass., April 23 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that surveyed cardiologists identify a therapy's effect on mortality as the attribute that most influences their prescribing decisions in the treatment of ST-elevation myocardial infarction (STEMI). Clinical data and the opinions of interviewed thought leaders indicate that The Medicines Company's Angiomax/Angiox has advantages in this attribute over Eli Lilly's ReoPro, the sales-leading agent in percutaneous coronary intervention (PCI) treatment of STEMI.

The new report entitled STEMI: Significant Opportunity Awaits Drugs That Can Reduce Mortality Rates also finds that an antiplatelet agent administered with stenting that is associated with lower rates of mortality and thrombocytopenia than ReoPro and less severe drug interactions would earn a substantial patient share in STEMI. According to surveyed U.S. and European cardiologists, this patient share would be 50 percent in the United States and 40 percent in Europe.

In 2008, Decision Resources' proprietary clinical gold standard for STEMI treated with PCI was Angiomax/Angiox. Based on available data and expert opinion, Angiomax/Angiox will retain gold-standard status for STEMI in 2017. While some therapies in development for the treatment of STEMI with PCI hold promise, most have efficacy, safety and tolerability, and/or delivery features that interviewed physicians indicate are inferior when compared with Angiomax/Angiox.

"Interviewed physicians regard Angiomax/Angiox as being highly efficacious because it is associated with significantly lower mortality rates than the standard PCI adjunctive therapy of unfractionated heparin and a glycoprotein IIb/IIIa inhibitor," said Decision Resources Analyst Jeremy Goldman, M.D. "This mortality reduction is associated with lower rates of bleeding with Angiomax/Angiox."

About the Report

STEMI: Significant Opportunity Awaits Drugs That Can Reduce Mortality Rates is a DecisionBase 2009 report. DecisionBase 2009 is a decision-support tool that provides in-depth analysis of unmet need, physician expectations of new therapies and commercial dynamics to help pharmaceutical companies optimize their investments in drug development.

The report can be purchased by contacting Decision Resources. Members of the media may request an interview with an analyst.

About Decision Resources

Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

    For more information, contact:

    Decision Resources               Decision Resources, Inc.
    Christopher Comfort              Elizabeth Marshall
    781-296-2597                     781-296-2563
    ccomfort@dresources.com          emarshall@dresources.com


'/>"/>
SOURCE Decision Resources
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. An ESC statement on gender differences in medical care and survival after myocardial infarction
2. New System Devised To Guide Doctors Treating Patients With Symptomatic Myocardial Bridging
3. New system devised to guide doctors treating patients with symptomatic myocardial bridging
4. Myocardial infarction: Mortality for women not higher than for men
5. Increased risk of myocardial infarction and diabetes in East Germany
6. Singulex Announces Presentation on Monitoring of Cardiac Biomarker to Assess Transient Myocardial Ischemia at the American Heart Association Scientific Sessions
7. Heart regenerates after infarction -- first trials with mice
8. ST elevation infarction
9. Interviewed Experts Expect Taxotere to Increase Overall Survival More Than Other Drugs, Including Lupron Depot, in Stage III Prostate Cancer
10. In Hepatitis C Virus Treatment, Interviewed Experts Indicate That Telaprevir- and Boceprevir-Based Regimens Have Advantages Over Pegasys/Ribavirin in Sustained Virologic Response
11. My1Stop.com President Michael Del Chiaro Interviewed by Entrepreneur.com for ecommerce Expertise
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... ... June 25, 2016 , ... ... issues and applications at AcademyHealth’s Annual Research Meeting June 26-28, 2016, at the ... several important health care topics including advance care planning, healthcare costs and patient ...
(Date:6/25/2016)... ... June 25, 2016 , ... As a lifelong Southern Californian, Dr. Omkar Marathe ... from the David Geffen School of Medicine at UCLA. He trained in Internal Medicine ... his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai program where he had the ...
(Date:6/24/2016)... ... ... Those who have experienced traumatic events may suffer from a complex set of ... or alcohol abuse, as a coping mechanism. To avoid this pain and suffering, Serenity ... event. , Trauma sufferers tend to feel a range of emotions, from depression, guilt, ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... ... now offering micro-osteoperforation for accelerated orthodontic treatment. Dr. Cheng has extensive experience with ... Damon brackets , AcceleDent, and accelerated osteogenic orthodontics. , Micro-osteoperforation is a ...
(Date:6/24/2016)... ... June 24, 2016 , ... The Haute Beauty Network, ... M. Weintraub as a prominent plastic surgeon and the network’s newest partner. ... the most handsome men, look naturally attractive. Plastic surgery should be invisible.” He ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... , June 23, 2016 , ... on Thursday, July 7, 2016 , , , , LOCATION: ... , , , , EXPERT PANELISTS:  , , , ... Senior Industry Analyst, Christi Bird; Senior Industry Analyst, Divyaa Ravishankar and ... The global pharmaceutical industry is witnessing an exceptional era. ...
(Date:6/23/2016)...  Guerbet announced today that it has been named ... . One of 12 suppliers to receive ... support of Premier members through exceptional local customer service ... to lower costs. ... outstanding customer service from Premier," says Massimo Carrara ...
(Date:6/23/2016)... NEW YORK , June 23, 2016 ... rough waters, but it continues to present great opportunities ... featured companies for today: Intrexon Corp. (NYSE: ... ), Arena Pharmaceuticals Inc. (NASDAQ: ARNA ), ... Learn more about these stocks and receive your complimentary ...
Breaking Medicine Technology: